Medicalsystem Biotechnology Co., Ltd. (300439.SZ)
CNY 11.23
(-1.66%)
CNY 11.23
(-1.66%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 475.01 Million CNY | -14.83% |
| 2022 | 430.61 Million CNY | 5.05% |
| 2021 | 442.32 Million CNY | -22.98% |
| 2020 | 590.22 Million CNY | 10.97% |
| 2019 | 572.19 Million CNY | -7.05% |
| 2018 | 574.9 Million CNY | 13.61% |
| 2017 | 514.78 Million CNY | 76.3% |
| 2016 | 308.36 Million CNY | 28.42% |
| 2015 | 237.17 Million CNY | 16.32% |
| 2014 | 203.47 Million CNY | 31.18% |
| 2013 | 151.33 Million CNY | 17.57% |
| 2012 | 129.58 Million CNY | 81.02% |
| 2011 | 73.48 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 78.98 Million CNY | 65.18% |
| 2024 Q3 | 60.5 Million CNY | -44.7% |
| 2024 Q2 | 116.29 Million CNY | -15.31% |
| 2023 Q4 | 56.72 Million CNY | -20.51% |
| 2023 FY | - CNY | -14.83% |
| 2023 Q1 | 62.02 Million CNY | 40.88% |
| 2023 Q3 | 71.36 Million CNY | -36.29% |
| 2023 Q2 | 112 Million CNY | 80.58% |
| 2022 FY | - CNY | 5.05% |
| 2022 Q2 | 101.97 Million CNY | 3.19% |
| 2022 Q4 | 44.02 Million CNY | -42.96% |
| 2022 Q1 | 98.82 Million CNY | 132.2% |
| 2022 Q3 | 77.19 Million CNY | -24.3% |
| 2021 Q3 | 67.38 Million CNY | -25.61% |
| 2021 FY | - CNY | -22.98% |
| 2021 Q1 | 93.66 Million CNY | 135.85% |
| 2021 Q2 | 90.58 Million CNY | -3.28% |
| 2021 Q4 | 42.55 Million CNY | -36.85% |
| 2020 Q4 | 39.71 Million CNY | -67.49% |
| 2020 Q3 | 122.16 Million CNY | 31.82% |
| 2020 FY | - CNY | 10.97% |
| 2020 Q1 | 206.86 Million CNY | 560.43% |
| 2020 Q2 | 92.67 Million CNY | -55.2% |
| 2019 Q3 | 145.98 Million CNY | 42.15% |
| 2019 FY | - CNY | -7.05% |
| 2019 Q4 | 31.32 Million CNY | -78.54% |
| 2019 Q2 | 102.69 Million CNY | -21.45% |
| 2019 Q1 | 130.74 Million CNY | 12.85% |
| 2018 Q1 | 92.6 Million CNY | -56.59% |
| 2018 Q4 | 115.85 Million CNY | 3.07% |
| 2018 Q2 | 144.4 Million CNY | 55.93% |
| 2018 Q3 | 112.41 Million CNY | -22.15% |
| 2018 FY | - CNY | 13.61% |
| 2017 Q3 | 73.31 Million CNY | -22.64% |
| 2017 FY | - CNY | 76.3% |
| 2017 Q1 | 62.55 Million CNY | -9.91% |
| 2017 Q2 | 94.78 Million CNY | 51.51% |
| 2017 Q4 | 213.33 Million CNY | 190.97% |
| 2016 Q3 | 74.84 Million CNY | -1.95% |
| 2016 FY | - CNY | 28.42% |
| 2016 Q2 | 76.32 Million CNY | 126.98% |
| 2016 Q1 | 33.62 Million CNY | -42.51% |
| 2016 Q4 | 69.43 Million CNY | -7.22% |
| 2015 Q1 | 44.72 Million CNY | 0.2% |
| 2015 Q4 | 58.49 Million CNY | 4.46% |
| 2015 Q3 | 56 Million CNY | 40.87% |
| 2015 Q2 | 39.75 Million CNY | -11.11% |
| 2015 FY | - CNY | 16.32% |
| 2014 FY | - CNY | 31.18% |
| 2014 Q3 | 65.03 Million CNY | 54.83% |
| 2014 Q4 | 44.63 Million CNY | -31.37% |
| 2014 Q1 | 40.21 Million CNY | 0.0% |
| 2014 Q2 | 42 Million CNY | 4.47% |
| 2013 FY | - CNY | 17.57% |
| 2012 FY | - CNY | 81.02% |
| 2011 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 1.86 Billion CNY | 74.465% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.84 Billion CNY | 83.312% |
| Dirui Industrial Co.,Ltd. | 288.83 Million CNY | -64.456% |
| Beijing Strong Biotechnologies, Inc. | 697.99 Million CNY | 31.946% |
| Maccura Biotechnology Co.Ltd | 651.98 Million CNY | 27.144% |
| Guangzhou Wondfo Biotech Co.,Ltd | 859.12 Million CNY | 44.71% |
| Guangdong Hybribio Biotech Co.,Ltd. | 236.08 Million CNY | -101.207% |
| BGI Genomics Co., Ltd. | 714.86 Million CNY | 33.552% |
| Amoy Diagnostics Co., Ltd. | 352.59 Million CNY | -34.718% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | -59 Million CNY | 904.98% |